IMC J110C
Alternative Names: IMC-J110CLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Immunocore
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
- 29 Jun 2020 Preclinical trials in Solid tumours in United Kingdom (Parenteral), before June 2020 (Immunocore pipeline, June 2020)
- 05 Sep 2018 Immunocore has patent protection for ImmTAC platform in Europe and China